Emergent playing key role in manufacturing COVID-19 vaccines via PPP set up for flu

If and when Americans are vaccinated against COVID-19, they might take a moment to thank another virus, H1N1 influenza.

The country’s poor response to an H1N1 outbreak in 2009, including vaccine delays and shortages caused by outmoded technologies and a lack of domestic capacity, prompted the U.S. government to invest hundreds of millions of dollars on vaccine R&D and to create surge capacity that is making the rapid development and manufacturing of COVID-19 vaccines possible. ...